.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Chinese Patent Office
Harvard Business School
Baxter
Teva
Chubb
Farmers Insurance
Queensland Health
Cantor Fitzgerald
Merck

Generated: June 27, 2017

DrugPatentWatch Database Preview

Rufinamide - Generic Drug Details

« Back to Dashboard

What are the generic sources for rufinamide and what is the scope of rufinamide freedom to operate?

Rufinamide
is the generic ingredient in two branded drugs marketed by Eisai Inc, Glenmark Pharms Ltd, West-ward Pharms Int, and Mylan Pharms Inc, and is included in five NDAs. There are four patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are six drug master file entries for rufinamide. One supplier is listed for this compound.

Summary for Generic Name: rufinamide

Tradenames:2
Patents:4
Applicants:4
NDAs:5
Drug Master File Entries: see list6
Suppliers / Packagers: see list1
Bulk Api Vendors: see list67
Clinical Trials: see list10
Patent Applications: see list495
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:rufinamide at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-001Nov 14, 2008DISCNYesNo7,750,028*PED► SubscribeY► Subscribe
Glenmark Pharms Ltd
RUFINAMIDE
rufinamide
TABLET;ORAL205075-001May 16, 2016ABRXNoNo► Subscribe► Subscribe
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-002Nov 14, 2008ABRXYesNo7,750,028*PED► SubscribeY► Subscribe
Eisai Inc
BANZEL
rufinamide
TABLET;ORAL021911-003Nov 14, 2008ABRXYesYes7,750,028*PED► SubscribeY► Subscribe
Eisai Inc
BANZEL
rufinamide
SUSPENSION;ORAL201367-001Mar 3, 2011RXYesYes7,750,028*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Chubb
Julphar
Baxter
Fish and Richardson
US Department of Justice
Deloitte
Covington
Mallinckrodt
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot